ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Dec 17, 2017
Dividend Increases/Decreases for the Week Ending December 15
Let's take a look at companies raising/lowering their dividends this week.
Dec 14, 2017
Comment: Verint's Traditional Free Cash Flow
Image shown: Page 1 of 16, Valuentum's 16-page stock report on Verint (VRNT). Verint is free cash flow positive, implying that non-GAAP earnings adjustments are of high quality.
Dec 12, 2017
CVS Health at the Crossroads, Too Much Debt
Image Source: CVS Health. We have been disappointed with the lack progress displayed by CVS Health thus far in 2017. We knew the business was entering into an earnings trough as a result of key contract losses, but recent events have unfolded that, in our view, have lessened the attractiveness of its business model, to a meaningful degree. Let’s talk more about what’s happening at CVS Health, the changing PBM market, Amazon’s threat, and too much leverage. We’re not overreacting, but we’re not happy either.
Dec 11, 2017
Video: Nelson's Active Management Theorem, Poker and "High Society," Inertia and the Value-Growth Conundrum
President of Investment Research Brian Nelson details his simple new theorem of the stock market that may change everything you believe. Nelson explains using poker as an example, and he goes on to caution about the concept of inertia, and how investing has somehow transformed into a "game" -- if investors truly believe there are 'value' and 'growth' stocks. A must-watch intrigue. Running time: ~11 minutes.
Dec 9, 2017
Addressing the Intricacies of the Dividend Cushion Ratio
The Dividend Cushion ratio continues to build an impressive track record of warning investors of impending dividend cuts, but it’s not perfect. Let’s examine a few recent cases.
Dec 9, 2017
BioMarin Pharmaceuticals: A Rare Drug Powerhouse
Image shown: BioMarin's stock price has had a choppy ride these past couple years. BioMarin continues its impressive string of hits in the rare drug market. We continue to be impressed with the depth of the scientific advances brought forth by the company. An in-depth discussion of BioMarin's pipeline is warranted, in our view, particularly in light of the potential for an expected, upcoming FDA approval.
Dec 7, 2017
Altria Back Above $70, Dollar General Pleases, Verint Sells Off
Image shown: Dollar General's stock has performed very well since being added to the Best Ideas Newsletter portfolio. We were very happy to see newsletter portfolio idea Altria surge back above $70 per share in recent days. Dollar General continues its strength as the economy churns out more of its demographic, and we continue to believe the dollar store arena may be one of the few spaces of retail that is truly insulated from the Amazon effect. Verint Systems, on the other hand, has faced selling pressure, which we think is flat-out unwarranted.
Dec 5, 2017
Video: North Korea, Indexing, and ETFs
President of Investment Research Brian Nelson talks about the non-zero probability of nuclear war, lofty equity market valuations, the impact of ultra-low interest rates, the Bitcoin phenomenon, the importance of paying attention to financial adviser fees, as well as the pitfalls when it comes to assigning styles to ETFs. Running time: ~11 minutes.
Nov 29, 2017
Documentary: The Bitcoin Phenomenom
Image Source: Vitalij Fleganov. Documentary: Produced for SQ1.tv, this Bitcoin documentary looks at the history, the ideologies, and the conflict between the politics of the early-adopters and the VCs/entrepreneurs pushing to take Bitcoin mainstream. Source: SQ1.tv.
Nov 29, 2017
Bitcoin's Price Leaps Toward $11,000
Image shown: Cryto-currencies are in vogue, and the most popular Bitcoin has "gone exponetial." This is incredible. Bitcoin has caught the financial markets by storm, and the ranks of the greedy are driving its price ever higher.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.